![]() |
市场调查报告书
商品编码
1316293
全球氧气疗法市场 - 2023-2030 年Global Oxygen Therapy Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2022 年,全球氧疗市场规模达到 296 亿美元,预计到 2030 年将达到 476 亿美元,实现利润丰厚的增长。在预测期内(2023-2030 年),全球氧疗市场的复合年增长率预计将达到 6.3%。家庭护理氧疗需求的增加、向轻型便携设备的转变以及对远程患者监测的日益关注是近期的一些市场趋势。
近年来,全球氧疗市场不断扩大。氧疗是一种医疗干预措施,包括为呼吸困难或血氧含量低的患者补充氧气。它用于改善流向人体各组织和器官的氧气流量,确保足够的氧含量,从而发挥适当的功能。
全球氧疗市场范围包括氧气输送设备等产品,其中包括氧气浓缩器、氧气瓶、液氧系统和氧气面罩,这些产品的使用增加了氧疗的市场份额。全球氧疗市场正在不断扩大,原因包括呼吸系统疾病发病率不断上升、老龄化人口不断增加、医疗保健支出不断增加以及技术进步等。
全球人口迅速老龄化,导致老年人呼吸系统疾病发病率上升。随着年龄的增长,人们的肺功能会逐渐衰退,因此需要进行氧疗。人口老龄化推动了对氧治疗设备和服务的需求,尤其是在发达国家。
例如,根据世界卫生组织(WHO)2022 年的报告,到 2030 年,地球上每六个人中就有一个是 60 岁或以上的老人。在这个时间跨度内,60 岁及以上人口占世界人口的比例预计将从 2020 年的 10 亿增加到 14 亿。因此,在预测期内,老龄化人口的增长预计将推动氧疗市场的增长。
全球医疗保健支出的增加使氧疗市场受益匪浅。各国政府和私营医疗保健提供商正投资于创新医疗技术,如氧疗设备,以满足日益增长的呼吸护理需求。新兴经济体可支配收入的增加和保险覆盖面的扩大也促进了氧气疗法支出的增加。
例如,2022 年 6 月,美国国际开发署(USAID)宣布了一项 5000 万美元的计划,旨在增加全球获得医用氧的机会,重点是在全球 50 个地区建设和改善医疗保健基础设施。这项投资预计将支持近 2 万张病床,使每年成千上万的患者能够获得救命的氧气。
此外,美国还是全球基金最大的捐助国,已捐助 6 亿多美元用于改善中低收入国家的医用氧气供应。自疫情开始以来,美国国际开发署已提供了 1.12 亿美元的直接资金,用于促进 50 个国家的氧气配送。这些重大投资表明了美国对扩大氧气治疗覆盖面的承诺,预计将对氧气治疗市场产生有利影响。
严格的法规阻碍了氧疗市场的发展。例如,2023 年 5 月,肺纤维化基金会的医疗咨询委员会发布了一份咨询声明,强调必须按照医护人员的处方使用经 FDA 批准的供氧设备。报告警告说,不要在没有处方的情况下购买供氧设备,这可能会导致严重的健康问题。
此外,未经 FDA 批准的供氧系统可能无法提供可靠的氧气供应,这就强调了使用认证设备的重要性。这些法律通过强调患者安全的必要性和通过公认渠道持续提供氧气治疗的重要性,起到了限制市场的作用。
COVID-19 疫情严重影响了全球氧疗市场。COVID-19 病例的增加增加了对氧气疗法的需求,而氧气疗法是治疗严重呼吸困难的一种急性疗法。因此,氧气出现短缺,需要迅速扩大氧气生产和基础设施。
市场的销售额和收入都出现了增长,而且在危机过去很久之后,这次大流行凸显了呼吸治疗和适当供氧的重要性。远程病人监护技术的进步进一步改变了市场。然而,不同地区的影响也不尽相同。总之,COVID-19 凸显了氧气治疗的重要性,并对全球行业产生了持久的影响。
俄乌冲突对氧疗市场产生了重大影响,破坏了医疗设施,造成人口流离失所,并使资源紧张。由于受伤、呼吸系统疾病和与压力有关的健康问题,冲突提高了对医用氧气的需求。然而,基础设施的损失和供应链的中断使得为有需要的人提供适当的氧气治疗变得十分困难。
此外,将资源分配给快速应急响应和人道主义援助可能会阻碍长期医疗基础设施的发展,降低提供全面氧气治疗服务的能力。对氧气治疗行业的具体影响将取决于冲突的持续时间和激烈程度,当地医疗保健提供者和国际援助组织在维持合规性方面发挥着至关重要的作用。
The global oxygen therapy market reached US$ 29.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 47.6 billion by 2030. The global oxygen therapy market is expected to exhibit a CAGR 6.3% during the forecast period (2023-2030). Increasing demand for homecare oxygen therapy, shift towards lightweight and portable devices, and growing focus on remote patient monitoring are some recent market trends.
The global oxygen therapy market has been expanding continuously in recent years. Oxygen therapy is a medical intervention that involves the giving of supplemental oxygen to those who have difficulty breathing or have low levels of oxygen in their blood. It is used to improve the oxygen flow to various body beings tissues and organs, ensuring enough oxygenation for appropriate functioning.
The global oxygen therapy market scope comprises components encompassing its products such as oxygen delivery devices, including oxygen concentrators, oxygen cylinders, liquid oxygen systems, and oxygen masks which has increased usage of oxygen therapy market share. The global market for oxygen therapy is expanding as a result of factors including increasing prevalence of respiratory diseases, growing aging population, rising healthcare expenditure, and technological advances.
The global population is rapidly aging, resulting in an increased prevalence of respiratory problems among the elderly. As people age, their lung function deteriorates, necessitating the need for oxygen therapy. The need for oxygen therapy devices and services is being driven by an aging population, particularly in developed nations.
For instance, according to World Health Organization (WHO) 2022 report, by 2030, about one out of every six people on the planet will be 60 or older. Within this time span, the share of the world population aged 60 and up is expected to increase from 1 billion in 2020 to 1.4 billion. As a result, the growing aging population is expected to fuel the growth of the oxygen therapy market over the forecast period.
The global increase in expenditure on healthcare has benefited the oxygen therapy market. Governments and private healthcare providers are investing in innovative medical technologies, such as oxygen therapy equipment, to address the growing need for respiratory care. Rising disposable incomes and expanded insurance coverage in emerging economies have also contributed to greater spending on oxygen therapy.
For instance, on June 2022, U.S. Agency for International Development (USAID) has announced a $50 million initiative to increase global access to medical oxygen, with a focus on the construction and improvement of healthcare infrastructure in fifty areas throughout the world. This investment is expected to support nearly 20,000 beds, allowing hundreds of thousands of patients each year to receive life-saving oxygen.
Furthermore, the U.S. is the greatest donor to The Global Fund, having contributed more than $600 million to improve access to medical oxygen in low- and middle-income nations. Since the beginning of the epidemic, USAID has provided direct funding of $112 million to boost oxygen distribution in 50 countries. These significant investments show a commitment to expanding access to oxygen therapy and are projected to have a beneficial influence on the oxygen therapy market.
The oxygen therapy market is hampered by stringent regulations. For instance, on May 2023, The Pulmonary Fibrosis Foundation's medical advisory board has issued an advisory statement emphasizing the necessity of utilizing only FDA-approved oxygen delivery equipment as prescribed by healthcare professionals. The report warns against buying oxygen supply equipment without a prescription, which might lead to significant health issues.
Furthermore, non-FDA-authorised oxygen delivery systems may not provide a reliable oxygen supply, emphasizing the importance of using certified equipment. These laws operate as market restraints by emphasizing the necessity of patient safety and the consistent delivery of oxygen therapy via recognized channels.
The COVID-19 epidemic severely impacted the global oxygen therapy market. The increase in COVID-19 cases increased the need for oxygen therapy, an acute treatment for severe respiratory distress. As a result, there were shortages, necessitating quick scaling of oxygen production and infrastructure.
The market saw an increase in sales and revenue, and the pandemic highlighted the significance of respiratory treatment and appropriate oxygen delivery long after the crisis had passed. Remote patient monitoring advancements altered the market even more. However, the influence differed by region. Overall, COVID-19 highlighted the importance of oxygen therapy and left an everlasting effect on the global industry.
The Russia-Ukraine conflict has had a major effect on the oxygen therapy market, disrupting healthcare facilities, displacing populations, and straining resources. Due to injuries, respiratory ailments, and stress-related health difficulties, the conflict has raised the demand for medical oxygen. However, infrastructure loss and disrupted supply chains have made it difficult to offer appropriate oxygen therapy to people in need.
Furthermore, allocating resources to rapid emergency response and humanitarian help may impede long-term healthcare infrastructure development, reducing the capacity to provide comprehensive oxygen treatment services. The specific impact on the oxygen therapy industry will vary depending on the length and intensity of the conflict, with local healthcare providers and international assistance organizations playing critical roles in maintaining compliance.
The global oxygen therapy market is segmented based on product, application, end user, and region.
The Chronic Obstructive Pulmonary Disorder (COPD) segment emerged as the market leader in oxygen therapy. COPD, a progressive lung disease characterized by airflow limitation, has a significant global impact, particularly among smokers and the elderly. COPD patients frequently require long-term oxygen therapy to enhance their oxygen levels and properly control their symptoms.
The global incidence of COPD has resulted in a significant demand for oxygen therapy devices and services tailored to this market segment. For instance, according to World Health Organization (WHO) statistics of 2023, COPD is the third leading cause of death worldwide. Furthermore, COPD has a significant impact, resulting in nearly 3.23 million deaths in 2019.
Moreover, it is worth emphasizing that low- and middle-income countries (LMICs) bear a disproportionately high burden of COPD, accounting for approximately 90% of COPD-related fatalities. Tobacco smoking is a key factor in COPD in high-income countries, accounting for more than 70% of cases. Also, with rising awareness of COPD and a growing need for respiratory assistance among affected persons, the COPD segment has established itself as the market's leading segment, driving overall growth and development.
North America is poised to dominate the oxygen therapy market due to rising awareness and a robust regulatory framework. For instance, companies such as Inogen, Inc. on January 2023, have gained key regulatory milestones in the EU and the US, increasing the availability and accessibility of portable oxygen concentrator equipment. This illustrates the company's dedication to providing novel respiratory treatments in the homecare sector.
Furthermore, initiatives such as Hyperbaric Knowledge USA's Hyperbaric Aware national campaign on May 2023, help to raise knowledge about hyperbaric oxygen therapy (HBOT) and its benefits. Collaboration with organizations such as the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders provides vital resources for both patients and clinicians, developing a greater understanding of oxygen therapy. Thus, owing to the above factors the market is expected to grow over the forecast period.
The major global players in the oxygen therapy market include: GE Healthcare, Invacare Corporation, Inogen, IUC Medical (Smiths Medical), HERSILL S.L., Fisher & Paykel Healthcare Limited, Philips Respironics, Inc., DeVilbiss Healthcare, Tecno-Gaz Industries, Allied Healthcare Products, Inc., and among others.
The global oxygen therapy market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE